Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Starting soon Not applicable

Tolerance and Acceptability of an Oral Nutrition Supplement

NCT07904715 · tracked via the Priya Life Science UK tracker
Phase
Not applicable
Started
2026-11
Last updated
2026-10-29

Condition(s) studied

Disease Related Malnutrition

Investigational drug(s) / intervention(s)

Oral nutritional supplementation

Oral nutritional supplementation: A Food for Special Medical Purposes taken orally, one or two servings a day as prescribed by the study dietitian, for 7 days.

Study summary

The goal of this study is to learn whether a new oral nutritional supplement is acceptable to adults who are malnourished, or at risk of malnutrition, and need nutritional support.

The main questions it aims to answer are:

* Do participants tolerate the supplement without stomach or bowel problems?
* How much of the prescribed supplement do participants take each day?
* How do participants rate the taste, texture and overall experience of taking the supplement?

Researchers will also record any side effects.

Participants will:

* Take the supplement every day for 7 days, as prescribed by their dietitian
* Keep a daily diary of how much they take and any stomach or bowel symptoms
* Complete a short questionnaire about the supplement and have a review with the study team on Day 7

Eligibility

Sex
ALL
Min age
18 Years
Max age
—
Healthy volunteers
No
Inclusion Criteria: * Aged 18 years or over * Male or female * Malnourished or at risk of malnutrition, identified using a validated screening tool (e.g. Malnutrition Universal Screening Tool (MUST) score of 1 or more), and/or currently using or requiring oral nutritional supplements as part of a nutritional management plan * Expected to take at least one serving of the study product per day (some participants may be prescribed two servings per day, depending on individual nutritional requirements) * Able to provide written or electronic informed consent, or verbal consent countersigned by an independent witness if physically unable to sign Exclusion Criteria: * Receiving exclusive enteral or parenteral nutrition (no oral intake) * Known allergy or intolerance to any ingredient in the study product, including milk, or any dietary requirement or preference incompatible with its composition (e.g. vegan) * Acute illness or unstable medical condition that may interfere with participation (e.g. major hepatic or renal dysfunction such as decompensated liver disease) * Currently in intensive care * Participation in another interventional clinical study within 2 weeks before this study * Insufficient proficiency in the English language * Lacking the mental capacity to provide informed consent * Investigator concerns about the participant's ability or willingness to comply with study requirements

Primary outcome measure(s)

  • Gastrointestinal tolerance — Baseline and daily from Day 1 to Day 7
    Participants record gastrointestinal symptoms each day in a diary: nausea, vomiting, bloating, abdominal pain, constipation, diarrhoea, and burping or flatulence. Each symptom is rated none, mild, moderate or severe. Bowel movement frequency and stool type are recorded each day using the Bristol Stool Chart. Results are reported as how often each symptom occurs and how severe it is, compared with symptoms recorded at baseline.
  • Compliance with the prescribed oral nutritional supplement — Daily from Day 1 to Day 7
    Participants record each day in a diary the number of servings prescribed and taken, and the reasons for any missed or partly taken servings. Compliance is reported as the percentage of prescribed servings each participant took over the study period.
  • Palatability of the oral nutritional supplement — Day 7
    Participants complete a questionnaire rating appearance, smell, taste, texture, aftertaste, convenience and how pleasant the supplement is to take. Each item is scored on a 5-point Likert scale from 1 (strongly disagree) to 5 (strongly agree). Overall satisfaction is rated on a 5-point scale from 1 (very dissatisfied) to 5 (very satisfied).

Trial sites (1)

FacilityCityRegionStatus
Nottingham University Hospitals NHS Trust Nottingham United Kingdom
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07904715 on ClinicalTrials.gov ↗ ← All trials in the UK